![Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-019-0069-2/MediaObjects/41392_2019_69_Fig1_HTML.png)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
![Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/907376aa-9756-4c9e-82b3-b2f6b5e0dd1a/gr2.jpg)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
![Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a5715e8f-7c65-4651-9fb9-2aea882637b7/gr1_lrg.gif)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
![Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial - Annals of Oncology Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ef6147a9-20b4-45f2-bde1-2ec422bf6820/gr1.jpg)
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial - Annals of Oncology
![Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCSABCS2013/2/2/Slide2.jpg)
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice
![Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download](https://images.slideplayer.com/37/10719684/slides/slide_37.jpg)
Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download
![Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/59730514-b6f5-4233-92a4-d3359fe836fc/gr1.jpg)
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
![Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/95f59ef1-cdc5-49a8-a205-50cb8b8aa4ef/gr1_lrg.jpg)
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology
![Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram](https://www.researchgate.net/publication/336920151/figure/tbl1/AS:820051573735424@1572526939433/Summary-of-the-CLEOPATRA-APHINITY-NeoSphere-and-TRYPHAENA-clinical-trials.png)
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
![CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download](https://images.slideplayer.com/38/10763040/slides/slide_8.jpg)
CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download
![Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f5bc0738-074b-423e-9fe8-dad5fc8c3268/gr2_lrg.jpg)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
![T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7a5f26b4-c209-4ebe-a035-033406e4a538/gr1_lrg.jpg)
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open
![Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bedf0b307bcd2706ba7837cb76dd60ae0bb44741/2-Figure1-1.png)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar
1 RESPONSE TO THE PUBLICATION OF THE CLEOPATRA CLINICAL TRIAL PAPER Executive Summary If a patient does not take a treatment th
![Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram](https://www.researchgate.net/publication/336920151/figure/tbl1/AS:820051573735424@1572526939433/Summary-of-the-CLEOPATRA-APHINITY-NeoSphere-and-TRYPHAENA-clinical-trials_Q640.jpg)